key: cord-0752342-byl4a5gp
authors: Llau, J. V.; Ferrandis, R.; Sierra, P.; Hidalgo, F.; Cassinello, C.; Gómez-Luque, A.; Quintana, M.; Amezaga, R.; Geroi, M.; Serrano, A.; Marcos, P.
title: SEDAR-SEMICYUC consensus on the management of haemostasis disorders in severe COVID-19 patients
date: 2021-10-25
journal: Med Intensiva (Engl Ed)
DOI: 10.1016/j.medine.2021.10.007
sha: 210f47010e6d983c5f9fd3b899cea0344fe63572
doc_id: 752342
cord_uid: byl4a5gp

nan

Llau JV 1, a , Ferrandis R 1, b , Sierra P 1, c , Hidalgo F 1, d , Cassinello C 1, e , Gómez-Luque A 1, f , Quintana M 2, g , Amezaga R 2, h , Geroi M 2, i , Serrano A 2, j , Marcos P 2, k . and no firm diagnosis can be established.

-Testing to confirm pulmonary thromboembolism is recommended in suspect cases due to progression of the hemostatic parameters (fundamentally D dimer) or on the basis of the clinical course of the patient, whenever possible. If confirmation is established, anticoagulation with LMWH is recommended as standard treatment.

-The maintenance of anticoagulation is recommended where required, preferably prescribing LMWH at therapeutic doses.

-The maintenance of antiplatelet treatment is recommended, administering acetylsalicylic acid in those patients where needed, and it is advisable to replace clopidogrel with prasugrel in those cases requiring dual therapy.

-It is advisable not to administer hemostatic agents to correct the coagulation test data in the absence of significant bleeding.

-In situations of active bleeding, when the administration of hemostatic agents proves necessary, the use of plasma as first choice is suggested versus prothrombin complex concentrates, due to the lack of experience and safety data. 

Recomendaciones de consenso SEDAR-SEMICYUC sobre el manejo de las alteraciones de la hemostasia en los pacientes graves con infección por COVID-19